Galmed Pharmaceuticals Stock Fundamentals
| GLMD Stock | USD 2.82 0.10 3.42% |
Galmed Pharmaceuticals fundamentals help investors to digest information that contributes to Galmed Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Galmed Stock. The fundamental analysis module provides a way to measure Galmed Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Galmed Pharmaceuticals stock.
Galmed |
Galmed Pharmaceuticals Company Current Valuation Analysis
Galmed Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Galmed Pharmaceuticals Current Valuation | (7.76 M) |
Most of Galmed Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Galmed Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Galmed Pharmaceuticals has a Current Valuation of (7.76 Million). This is 100.05% lower than that of the Biotechnology sector and 100.17% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.05% higher than that of the company.
Galmed Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Galmed Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Galmed Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Galmed Pharmaceuticals competition to find correlations between indicators driving Galmed Pharmaceuticals's intrinsic value. More Info.Galmed Pharmaceuticals is rated # 3 in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Galmed Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Galmed Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Galmed Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Galmed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Galmed Pharmaceuticals by comparing valuation metrics of similar companies.Galmed Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Galmed Fundamentals
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (7.76 M) | ||||
| Shares Outstanding | 1.66 M | ||||
| Shares Owned By Insiders | 1.28 % | ||||
| Shares Owned By Institutions | 0.48 % | ||||
| Number Of Shares Shorted | 6 K | ||||
| Price To Earning | (6.79) X | ||||
| Price To Book | 0.26 X | ||||
| EBITDA | (6.87 M) | ||||
| Net Income | (6.91 M) | ||||
| Cash And Equivalents | 22.4 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 41 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.48 X | ||||
| Book Value Per Share | 33.01 X | ||||
| Cash Flow From Operations | (6.14 M) | ||||
| Short Ratio | 0.27 X | ||||
| Earnings Per Share | 69.72 X | ||||
| Target Price | 12.0 | ||||
| Beta | 0.8 | ||||
| Market Capitalization | 4.84 M | ||||
| Total Asset | 16.63 M | ||||
| Retained Earnings | (192.95 M) | ||||
| Working Capital | 10.49 M | ||||
| Current Asset | 23.38 M | ||||
| Current Liabilities | 2.54 M | ||||
| Net Asset | 16.63 M |
About Galmed Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Galmed Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galmed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galmed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel. Galmed Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:Check out Galmed Pharmaceuticals Piotroski F Score and Galmed Pharmaceuticals Altman Z Score analysis. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.